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The transcription of immunoglobulin genes is controlled by variable region promoters and by enhancers,
both of which are lymphoid specific. Because immunoglobulin genes are subject to an extremely complex
regulation, we anticipated that there might be additional control elements for these genes. We therefore sought
additional enhancers and demonstrate here that there is indeed another weak transcriptional enhancer just 3'
to the mouse a constant region. This novel immunoglobulin enhancer is lymphoid specific and at two positions
can bind members of the Oct family of transcription factors.
The immunoglobulin (Ig) genes constitute one of the
best-studied systems with respect to cell-type-specific gene
expression. Functional Ig genes are created only in B
lymphocytes by somatic DNA rearrangements which assem-
ble together, during the early stages of B-cell development,
variable (V) and constant (C) region DNA segments (1, 43).
Several studies have shown that there is a good correlation
between nonproductive (so-called sterile) transcription of
the Ig locus (accompanied by hypomethylation) and its first
rearrangement (1, 4, 47). In line with this finding, agents
which are known to stimulate transcription of the kappa light
chain locus also stimulate its DNA rearrangement (35).
Transcription of Ig genes is controlled by V region pro-
moters and by enhancers which are lymphoid specific (3, 11).
Originally a strong lymphoid-specific enhancer was identi-
fied in the J-C intron of the heavy chain gene (3, 11, 26), and
a rather weak enhancer was also found in a similar location
in the kappa light chain gene (29, 32). The existence of cell
lines which had deleted the heavy chain intron enhancer and
yet retained high levels of Ig expression (18, 44) led to the
suggestion that the Ig locus could contain other enhancers
(14).
Recently new lymphoid-specific enhancers have been dis-
covered 3' of the kappa gene (22), 3' of the heavy chain locus
(6, 28) and also 3' of the lambda light chain gene (15). It is
generally assumed, but has not been demonstrated, that
these various enhancers may each play a role at a different
stage of B-cell development.
In spite of this complex picture, it seems likely that the
control elements identified thus far do not account for all the
regulatory pathways governing Ig gene expression. For
example, essentially no information is available about the cis
elements which control the switch recombination underlying
isotype switching (33). However, similar to the situation
encountered with the V-J and V-D-J rearrangements, hy-
pomethylation and transcription of the locus seem to accom-
pany or precede the actual recombination (40, 41). Further-
more treatments with certain cytokines can direct switch
recombination to particular C regions (21, 46), presumably
by activating enhancers which control the sterile transcrip-
tion of these genes and thus, indirectly, their rearrangement.
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Also, it is possible that the DNA sequences which control
the temporally regulated appearance of Igs (heavy chain first
and then only light chain [1]) are different from the promot-
ers and enhancers identified thus far. Furthermore, the cis
elements which control the somatic hypermutation process
are not definitively identified.
In an attempt to identify control elements which may be
involved in the regulation of switch recombination, we have
searched for additional enhancers around the most 3' C
region genes. Here we present evidence that the mouse
genome contains another enhancer very close to the Ca
gene. This enhancer, which we call the Cot 3' enhancer, is
quite weak and is, like the other Ig enhancers, lymphoid
specific. At present, we do not know whether this enhancer
is indeed involved in the control of switch recombination to
the Ca region. Interestingly, this enhancer has sequences
with homology to several sites found in other lymphoid-
specific promoters or enhancers, and it binds Oct factors in
vitro.
MATERIALS AND METHODS
Plasmids. The J21 reporter plasmid containing the chlor-
amphenicol acetyltransferase (CAT) gene under the control
of the c-fos promoter has already been described (20, 30, 45).
All additional clones were made by inserting DNA fragments
(made blunt ended with T4 DNA polymerase) into the
EcoRV site of J21, 3' of the CAT gene (ca. 2.5 kb away from
the c-fos promoter). For some experiments, we also used
another CAT reporter plasmid based on the thymidine
kinase (TK) promoter (extending up to -105; TK3). In those
cases, the cloning site used was a filled-in HindIII site
immediately upstream of the TK promoter. Mouse heavy
chain locus DNA fragments were isolated by standard pro-
cedures (34) from phage Ch3'Cao12A (16; kindly provided by
K. Calame) or from phage Ch.M.Ig E-12 or Ch.M.Ig -y2b-2
(38; obtained through the Japanese Cancer Research Re-
sources Bank). The control plasmids J21-SVO.17 and TK3-
SVO.17 contain a ca. 170-bp simian virus 40 enhancer
fragment (recovered from plasmid pBlue-SV by EcoRI
cleavage) into J21 or TK3. Similarly, the control plasmids
J21-IgO.7 and TK3-IgO.7 contain the ca. 700-bp EcoRI-XbaI
fragment from the mouse IgH intron enhancer (3, 11).
1547
Vol. 13, No. 3
1548 MATTHIAS AND BALTIMORE
Cell lines, transfections, and CAT assays. S194 is a mouse
B-cell plasmacytoma line, BJA-B is a mature human lym-
phoblastoid B-cell line, J558 is a mouse myeloma line, HeLa
is a human epithelial (cervix carcinoma) cell line, NIH 3T3 is
a mouse fibroblast line, BW5147 is a mouse lymphoma line,
and U937 is a human macrophage line. Cells (ca. 2 x 107
cells per sample) were transfected with DEAE-dextran fol-
lowed by a chloroquine boost (2), using either 0.5 or 1.0 ,ug
of DNA per kb of plasmid size (the total amount of DNA was
kept constant in each transfection by the addition of soni-
cated herring sperm DNA).
At 42 to 48 h after DNA addition, protein extracts were
prepared by three cycles of freezing-thawing and subsequent
incubation at 550C for 8 min (to inactivate an inhibitory
activity present in some lymphoid extracts). CAT assays
were set up with equivalent amounts of protein extract
(usually 150 to 250 pug; protein amounts were determined
with a Bio-Rad protein determination kit and gamma globu-
lin as a standard) and incubated at 370C for 1 to 2 h,
depending on the experiment. The resulting samples were
separated on thin-layer chromatography plates, fluorograms
of which are presented. For quantitation, the radioactive
spots were cut out and counted in a liquid scintillation
counter. All transfections experiments were performed a
minimum of three times.
DNA sequencing. The originally identified 1-kb XbaI frag-
ment was subcloned into the BluescriptKS- vector (Strata-
gene) to produce pBluelOOO+ or pBluelOOO-. A series of
nested deletions was then generated in these plasmids with
enzymes from a commercial kit (Pharmacia), and the result-
ing plasmids were sequenced on both strands with Seque-
nase version 2.0 (U.S. Biochemicals).
Nuclear extracts and electrophoretic mobility shifts assays
(EMSAs). Nuclear extracts were prepared by a small-scale
procedure (37) from various cell lines. Radioactive DNA
probes were prepared by digesting plasmid pBluelOOO+
(containing the 1-kb XbaI 3' enhancer fragment in Blue-
scriptKS-) with the appropriate restriction enzymes. After
dephosphorylation, the fragments were labeled with
[-y-32P]ATP and polynucleotide kinase and recovered from
polyacrylamide gels. Binding reactions (15 ,ul) were set up
with 4 to 6 ,ug of protein extract, 5,000 to 10,000 cpm of probe,
2 ,ug of poly(dI-dC), and 0.3 ,ug of denatured herring sperm
DNA in a buffer containing 4% Ficoll 400, 20 mM N-2-
hydroxethylpiperazine-N'-2-ethanesulfonic acid (HEPES; pH
7.9), 50 mM KCl, 1 mM EDTA, and 0.25 mg of bovine serum
albumin per ml. For competition experiments, the conditions
were exactly the same as above except that competitor DNA
was included in the reaction mixture (in the amounts indi-
cated in the figure legends) before addition of the nuclear
extract. The octamer site competitor DNA was a double-
stranded oligonucleotide corresponding to nucleotides 533 to
554 of the mouse IgH enhancer (10); the NF-KB competitor
DNA was a double-stranded oligonucleotide as described
elsewhere (11), and the Ca3' enhancer competitor DNA was
the 1-kb XbaI fragment recovered from pBluelOOO+. After
10 min at room temperature, the samples were loaded onto
prerun 4% polyacrylamide gels containing 22.5 mM Tris-
borate and 0.5 mM EDTA (0.25 x TBE). Fluorograms of
dried gels are presented.
In vitro translation reactions were set up with micrococcal
nuclease-treated reticulocytes lysates (Promega) according
to the manufacturer's instructions. The RNAs used to pro-
gram the lysates were obtained by transcribing linearized
pBS-Oct-1 (42) or pGem-C+ (23; used to obtain Oct-2 RNA).
About 1/20 of each in vitro translation was used for the
EMSA.
Nucleotide sequence accession number. The sequence has
been deposited in the EMBL data base under accession
number Z14251.
RESULTS
Identification of an enhancer immediately 3' of the Cot
region. We have used transient transfection assays into B
cells to search for a novel transcription enhancer in the
heavy chain locus. Fragments from X phages containing
DNA from the mouse heavy chain locus were inserted into
the reporter plasmid J21, in which the CAT gene is driven by
the fos promoter (sequences from -71 to +109 [20, 30]).
This plasmid responds well to stimulation by an enhancer
and has been used previously, for example to identify a
T-cell receptor at chain enhancer (45). A few initial experi-
ments were made with DNA fragments from around the e
and -y2b constant regions (phages Ch.M.Ig e-12 and Ch.M.Ig
y2b-2 [38]), but no fragment that could increase CAT expres-
sion significantly in transfected B cells was identified. We
then concentrated our analysis on a phage containing mouse
DNA from around the Ca region and extending for ca. 10 kb
further downstream. Three DNA fragments from this phage
were able to reproducibly stimulate CAT expression from
the reporter plasmid when introduced into S194 mouse
plasmacytoma B cells (Fig. 1A): a ca. 7-kb EcoRI fragment
(J21-7.0 E), a 2.8-kb HindIII fragment (J21-2.8 H), and a 1-kb
XbaI fragment (J21-1.0 XXa or J21-1.0 XXb). These three
fragments are overlapping, and as shown in Fig. 1A, the 1-kb
X7aI fragment stimulates CAT expression in either orienta-
tion (reproducibly somewhat better in orientation b than in
orientation a). Furthermore, these three overlapping frag-
ments also stimulated CAT expression in other B cell lines
such as X63Ag8, BJA-B, and J558, while the other DNA
fragments from this phage had no stimulatory effect on CAT
expression in any of the cell lines tested (Fig. 1 and data not
shown). To further substantiate these data, some of these
mouse DNA fragments were also tested in a reporter plasmid
in which the CAT gene is under the control of the TK
promoter. As is shown in Fig. 1B, the 2.8-kb HindIII
fragment and the 1-kb XbaI fragment (TK3-2.8 H and
TK3-1.0 XX) both stimulated CAT activity, while the previ-
ously negative 3.0-kb HindIII fragment (TK3-3.0 H) was still
negative. This result indicates that the effects observed were
not promoter specific. In additional experiments using the
TK-based reporter plasmid, it was also apparent that the
activity of the 7-kb EcoRI fragment (used in Fig. 1A) was
partially dependent on its orientation (not shown).
To further define the region of the 1-kb XbaI fragment
important for activity, we tested a number of subfragments
for the ability to increase CAT expression from the J21
plasmid. As shown in Fig. 2, a 0.68-kb BglI-XbaI fragment
(J21-0.68 BX) as well as a 0.6-kb XbaI-RsaI fragment (J21-
0.6 XR) both retained most of the enhancer activity in S194
cells. As these two fragments are overlapping, they define
the central region of the XbaI fragment as the one containing
most of the activity. Accordingly, a central StyI-XhoII
310-bp fragment (J21-0.31 SXh) still had significant enhancer
activity, which increased somewhat when the fragment was
duplicated (J21-0.31 SXh2.). However, the slightly higher
activity of the complete XbaI fragment indicates that the
flanking regions are needed for maximal activity.
The 1-kb XbaI fragment stimulates CAT activity between
6- and about 20-fold above the background of the J21 or TK3
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FIG. 2. Fine structure mapping of the Ca 3' enhancer to delin-
eate the active region of the enhancer. The top bar represents the
1-kb XbaI fragment. Subfragments of this XbaI fragment were
assayed for enhancer activity in S194 cells as described in the legend
to Fig. 1. X, XbaI; S. StyI; B, BglI; R, RsaI; Xh, XhoII; A, AccI.
For J21-0.39 XB and J21-0.68 BX, the results obtained with two
independent plasmid isolates are presented. Cm, [14C]chloram-








FIG. 1. Identification of an enhancer 3' of the Ca region. Various
restriction fragments from around the Ca region (recovered from
phage Ch3'Ca12A [16]) were inserted into the J21 reporter plasmid
(A) or into the TK3 reporter plasmid (B). The resulting constructs
were introduced into S194 plasmacytoma cells. Subsequently,
equivalent amounts of cell extracts were assayed for the ability to
convert [14C]chloramphenicol (Cm) to the acetylated form (Ac-Cm).
The bar underneath the map of the Ca locus represents the portion
of genomic DNA which is present in phage Ch3'Ca12A (16) (the
leftmost and rightmost EcoRI sites are derived from the cloning
procedure). E, EcoRI; X, XbaI; H, HindIII. In the plasmid names,
the suffixe a or b refers to either orientation of the inserted fragment.
vector, and this level represents under our experimental
conditions ca. 5 to 15% of the stimulation obtained with the
IgH intron enhancer. We call this novel Ig 3' enhancer the
Ca 3' enhancer.
The Ca 3' enhancer appears to be B cell specific, as it is
active (to various degrees) in several B-cell lines (S194,
BJA-B, J558, and X63Ag8) but not in HeLa, Cos-7, U937,
NIH 3T3, or BW5147 cells (Fig. 3 and data not shown). Note
that for HeLa cells, data obtained with both the J21 and TK3
reporter plasmids are presented; in neither case can any
activity from the XbaI fragment be detected above the basal
level of the reporter plasmid (Fig. 3). Because this enhancer
is rather weak, we considered the possibility that it might be
inducible and would show maximal activity only in the
presence of the appropriate inducer(s), in analogy to the K
light chain intron enhancer, which in pre-B cells is inducible
by bacterial lipopolysaccharide (LPS) (20). We therefore
transfected B-cell lines with the Cat 3' enhancer constructs
J21-1.0 XXa and J21-1.0 XXb as well as with controls and
treated the cells with agents such as LPS, phorbol 12-
myristate 13-acetate, interleukin-4, or transforming growth
factor 1. However, none of these agents, either singly or in
combination, significantly increased the activity of the Ca 3'
enhancer in any of the cell lines tested (data not shown).
The location of this new enhancer, close to the Cat gene,
suggested that it might be involved in controlling switch
recombination to Cat, perhaps by activating sterile transcrip-
tion of the region. In that scenario, the Ca 3' enhancer could
be more active in cells which switch to the Ca region,
because they would contain a nuclear factor (or a combina-
tion of factors) which activate it. To test that hypothesis, we
used two cell clones derived from 129, a cell line which can
undergo, upon stimulation with LPS, switch recombination
in culture mostly to Ca and to a lesser extent to Ce (40, 41).
The first clone, 22D, is a variant which does not switch and
makes the p. isotype; the second clone, BFO-3, has switched
to Cao and stably makes the at isotype. We transiently
introduced the J21-1.0 XXa and J21-1.0 XXb plasmids into
these two cell lines and determined the resulting activity.
Despite the low transfection efficiency of these cells, it was
apparent that the Cat 3' enhancer was not significantly more
active in BFO-3, the IgA-producing line, than in the p.-pro-
ducing line 22D (not shown).
Sequence of the Ca 3' enhancer and protein binding anal-
ysis. We determined the nucleotide sequence of the central
StyI-AccI 447-bp fragment, which has most of the enhancer
activity (Fig. 4). Inspection of the sequence revealed several
potentially interesting motifs. In particular, three sequences
with homology to the octamer site (7, 27) are present. The
first one, around position 188 (-CT'l'lGAAT-), is in the same
orientation as the octamer site in the intron heavy chain
enhancer (3, 10, 11) and has a 6-of-8-bp match to the
consensus -AllTTGCAT- (Fig. 3). The second and the third,
at positions 292 and 415, respectively (lower-strand number-
ing), are both in the opposite orientation and also have a




































































FIG. 3. Cell specificity of the Ca 3' enhancer. Plasmids were
transfected into B-cell (J558 and S194) and non-B-cell (HeLa and
U937) lines, and extracts were assayed as described in the legend to
Fig. 1. For HeLa cells, results obtained both with the J21 and TK3
reporter plasmids are presented. Cm, ['4C]chloramphenicol; Ac-
Cm, acetylated chloramphenicol.
Several homologies to the ptE5 and KE2 motifs (24), which
are binding proteins of the helix-loop-helix family (24, 25),
are also found, around positions 142 (lower strand), 201, and
323. Also, a perfect binding site for the AP-1 family of
transcription factors (9) is found at position 160 (Fig. 4).
To get a preliminary picture of the nuclear factors that are
able to bind on the central portion of the Ca 3' enhancer, we
prepared overlapping fragments from the StyI-AccI fragment
and used them in EMSAs. As a source of extract, we used
mostly BJA-B cells, because extracts of good quality are
easily prepared from them and because the Cao 3' enhancer is
active in these cells. While essentially every fragment tested
was to a certain extent shifted in the presence of extract,
some of the fragments gave a pattern of retarded bands
which was consistent with the binding of octamer factors and
were thus analyzed further. Two overlapping fragments, a
199-bp HphI-HphI fragment (Fig. SA) and a 121-bp Hinfl-
RsaI fragment (Fig. SB), both gave rise to two major
retarded species in the presence of B-cell extract (lanes 2).
Addition of an increasing amount of an oligonucleotide
containing an octamer site derived from the IgH intron
enhancer efficiently abolished the binding (lanes 3 and 4),
while addition of an oligonucleotide containing an NF-KB
site (11) did not affect the EMSA pattern (lanes 5 and 6).
With the 121-bp Hinfl-RsaI fragment (Fig. SB), an additional
retarded species was also clearly observed (running between
the two other major species), which was not affected by
addition of the competitor DNAs mentioned above. How-
ever, when the 1-kb XbaI Cot 3' enhancer fragment was used
as a competitor (lane 7), every retarded species was abol-
ished, including this one, indicating that it is likely to be a
specific complex (it could, for example, be a protein binding
to the E box homology also present on that fragment). We
have not yet investigated this binding species further. For
comparison, Fig. 5C shows identical EMSA reactions that
were performed with a high-affinity octamer site probe
derived from the intron heavy chain enhancer (10); the
retarded species due to Oct-1 (8) and two of the Oct-2
isoforms, Oct-2A (5, 23, 39) and Oct-2B (36), are clearly
identified and are labeled accordingly in Fig. 5C. Because
the three probe fragments used differ widely in length, the
respective retarded complexes migrate at slightly different
positions in the gel. Additional competition experiments
were done with a number of other fragments or oligonucle-
otides (including an oligonucleotide containing the cognate
sequence, not shown); all of the results obtained are consis-
tent with the relatively low affinity binding of the octamer
factors Oct-2A (faster-migrating complex; Oct-2B is barely
visible) and Oct-1 (slower-migrating complex) around posi-
tion 188 of the Ca 3' enhancer to the degenerate octamer
sequence -CTllTGAAT-. The binding of octamer factors was
further confirmed by EMSA with Oct-1 or Oct-2 protein
made in a reticulocyte lysate. In vitro-translated Oct-1 and
Oct-2 proteins both bound specifically to the 121-bp Hinfl-
RsaI fragment (Fig. 5D, lanes 3 to 5). In addition, this
experiment shows that octamer factors can bind with a lower
CCTTGGGTGA TGGGGGTTGG GGCCTCCTCA GCCCCTGGCA GGCTCCCCTG
GCTCCCACCC CTCATCCATGTCCCAGGCCC ACCTGGCCTG GTCCAGTGTG
ATGTGATTCT CAGAACAGTA GCTCTGGTTT GGGGCACCTG TGCTGAGACA
GGCTCAG GAU GCTG CCCTCAGCTG AGAGCTGCTTTGAATGTTTC
AGCAGGTGAT AGACAACAGA GACTTCAGAA GAGAGAAAAA CAAGTTGCTA
. ..........
ATGTGAGCAT CCCTGCCCTACCCCCACACC TGTACTGCAA ACATTGTTGA
CCCCAGATAG AGATCCCAGG ACAGCAGGTG ATAGACAAAG GAGGCTCCAG
............
AGGAGAGAAA AATAGTATCT ATAAGCATGA CTACCTCTGC CCTGCCCCAC
























IgH intron TGCAGGTGT Ca3enh 20,AGCAGGTGA
CaX3enh 142CACAGGTGC IC inltron GGCAGGTGG
inverse
CaT3enh 323AGCAGGTG:A
FIG. 4. Nucleotide sequence of the Ca 3' enhancer 447-bp
central StyI-AccI fragment (the location of this fragment is indicated
in the diagram in Fig. 2). Regions with homologies to known motifs
are highlighted with dotted lines (KE2 and p.E5 sites), solid lines
(octamer sites), or a box (AP-1 site). Under the sequence, the
homologies are compared with canonical sites, with identities indi-
cated by dots. Note that in some cases (labeled inverse), the
sequence of the lower strand is indicated with the numbering
adjusted accordingly.
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FIG. 5. In vitro binding of octamer factors to the Ca 3' enhancer StyI-AccI fragment. (A to C) EMSAs with BJA-B nuclear extract and
the following labeled DNA fragments as probes: a 199-bp HphI-HphI fragment (199 H-H) (A), a 121-bp Hinfl-RsaI fragment (121 Hi-R) (B),
and a 47-bp DdeI-Hinfl fragment (containing a perfect octamer site) (C) from the mouse intron heavy chain enhancer (10). Lanes: 1, no nuclear
extract; 2 to 7, BJA-B (B-cell) nuclear extract. In lanes 3 to 7, various competitor DNAs were added, the nature of which is indicated above
the lanes. The amounts of specific competitor DNA added were as follows: lanes 3 and 5, 100 fmol; lanes 4 and 6, 500 fmol (about a 50-fold
excess); and lanes 7, 450 fmol. The diagram depicts the StyI-AccI fragment. The positions of homologies to known motifs are indicated as
follows: solid circles, octamer sites; solid squares, KE2 and ptE5 sites; and open square, AP-1 site. Underneath are indicated the positions of
the restriction sites used as well as the lengths (in base pairs) of the resulting fragments. H, HphI; Hi, Hinfl; R, Rsal. (D and E) EMSAs with
reticulocytes lysates or B-cell extracts, using a 121-bp Hinfl-RsaI probe (121 Hi-R) (D) and a 121-bp HpaI-HpaI probe (121 H-H) (E). Lanes:
1, no extract or reticulocyte lysate added; 2, BJA-B nuclear extract; 3 to 6, rabbit reticulocyte lysate (RRL). The origin of the RNA used to
program the lysate is indicated above each lane.
affinity at a second position on the Cat 3' enhancer. Figure SE
shows that the 121-bp HpaI-HpaI fragment binds octamer
factors (from BJA-B extract [lane 2] or in vitro translations
[lanes 3 to 5]) with very low affinity. Here too, extensive
competition experiments verified the identity of the com-
plexes observed (not shown).
The fact that the two octamer sites identified are in relative
proximity (slightly less than 100 bp apart [Fig. 4]) raised the
possibility of cooperative binding on the natural fragment, in
particular because it had previously been shown that oc-
tamer factors can bind cooperatively to their cognate sites in
certain cases (17, 19, 31). We therefore prepared as a probe
a restriction fragment which contained both sites; however,
EMSA analysis failed to reveal cooperative binding. The
third octamer site homology at position 408 does not appre-
ciably bind octamer factors under our conditions (data not
shown), even though it has a sequence identical to the
sequence of the site at position 285. Therefore, the context
of these two sites (flanking sequences) must account for their
difference in binding capacity.
We have not yet further analyzed what other factors
specifically bind to the Cao 3' enhancer; this analysis requires
additional work.
DISCUSSION
In this report, we have presented evidence that the mouse
genome contains another 3' enhancer very close to the Ca
region. This enhancer is different from the recently identified
3' enhancer which is ca. 25 kb downstream of the Cat gene in
the rat genome (28) and ca. 16 kb downstream of it in the
mouse genome (6).
Analysis of this Cao 3' enhancer in several cell lines
demonstrated that it was lymphoid specific, like the other Ig
enhancers, but quite weak. Under the conditions that we
used, it did not appear to be inducible. DNA sequence
analysis of the central region revealed sequences with ho-
mology to several known motifs which have also been found
in other Ig enhancers: octamer-like sites, KE2/jlE5-like sites,
and also one perfect AP-1 site. In vitro binding analysis with
nuclear extracts showed that two of the three octamer site
homologies can bind their cognate factors with relatively low
affinity. Moreover, preliminary results suggest a functional
importance for these sites, because their mutation somewhat
reduces the activity of the Ca 3' enhancer in transfected
S194 cells (data not shown). Clearly other factors also bind
on the Cat 3' enhancer, but they have not yet been analyzed
further.
Previous studies had shown by run-on analysis that my-
eloma cells which had spontaneously deleted the region
immediately 3' of the Ca gene (including the membrane exon
and encompassing the region where the Ca 3' enhancer is
located) had a severalfold-decreased rate of alpha gene
transcription (13). It had then been suggested that these
deleted sequences could have contained transcription-en-
hancing sequences, or else that the newly juxtaposed se-
quences could have contained transcription-inhibiting se-
quences (13). In light of our results, it now appears likely
that the former hypothesis was correct, and this observation
suggests that the Cax 3' enhancer probably has a biological
role. However, the presence or absence in these myeloma
cells of the Cat 3' enhancer (as well as the presence or
D
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absence of the other, further-downstream 3' enhancer [6])
remains to be tested directly.
The mouse DNA around the Ca region had in fact already
been screened for enhancer activity and had been scored
negative (16). We do not know the reason for the discrep-
ancy with our results but suspect that it might have to do
with the different cell lines or with the different reporter
plasmids used (see also reference 16). Furthermore, because
this enhancer is quite weak, it could easily have been
overlooked, especially if the reporter plasmid yielded a high
background.
Why is there yet another enhancer element, near the Cao
region gene? At least two possibilities can be considered.
The simplest one is that this enhancer is just one more
control element for Ig genes, which contributes, in concert
with the other Ig enhancers, to maximal Ig expression.
Another possibility is that the Cot 3' enhancer is implicated in
controlling some aspect of the switch recombination process
(perhaps the accessibility of the ax locus, through sterile
transcription). In that case, one might expect this enhancer
to be maximally active in cells which are switching or have
switched to the ao locus. Unfortunately, when we tested the
Cao 3' enhancer in two cell lines (one of the a isotype and the
other of the p. isotype) derived from the same parental line,
we did not observe a significant difference in activity.
However, one should bear in mind that the activation of such
an enhancer could be a transient phenomenon that might
escape detection by the use of cell lines. Definitive evalua-
tion of the role of this enhancer for Ig expression awaits
experiments with transgenic mice or its targeted disruption
in the mouse germ line.
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